publication . Article . Other literature type . 2018

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Brian Godman; Brian Godman; Brian Godman; Brian Godman; Anna Bucsics; Patricia Vella Bonanno; Wija Oortwijn; Wija Oortwijn; Celia C. Rothe; Alessandra Ferrario; ...
Open Access English
  • Published: 05 Dec 2018
Abstract
Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this ...
Persistent Identifiers
Subjects
Medical Subject Headings: health care economics and organizations
free text keywords: Public Health, Review, managed entry, health policy, pharmaceuticals, financing, cancer, orphan diseases, new models, managed entry ; health policy ; pharmaceuticals ; financing ; cancer ; orphan diseases ; new models, 1117 Public Health and Health Services, Science & Technology, Life Sciences & Biomedicine, Public, Environmental & Occupational Health, managed entry, health policy, pharmaceuticals, financing, cancer, orphan diseases, new models, MULTICRITERIA DECISION-ANALYSIS, HEALTH TECHNOLOGY-ASSESSMENT, MANAGED ENTRY AGREEMENTS, ENHANCE PRESCRIBING EFFICIENCY, RISK-SHARING ARRANGEMENTS, MIDDLE-INCOME COUNTRIES, PUBLIC-HEALTH, CANCER DRUGS, CASE-HISTORY, RHEUMATOID-ARTHRITIS, RM, RA0421, Health care, business.industry, business, Public economics, Scrutiny, Financial modeling, Narrative review, Health policy, Peer review, Multicriteria decision, Orphan diseases, lcsh:Public aspects of medicine, lcsh:RA1-1270
283 references, page 1 of 19

1.Garattini S Bertele V Godman B Haycox A Wettermark B Gustafsson LL. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol. (2008) 64:1137–8. 10.1007/s00228-008-0537-z 18688606 [OpenAIRE] [PubMed] [DOI]

2.Godman B Malmstrom RE Diogene E Gray A Jayathissa S Timoney A. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?Expert Rev Clin Pharmacol. (2015) 8:77–94. 10.1586/17512433.2015.990380 25487078 [OpenAIRE] [PubMed] [DOI]

3.Malmstrom RE Godman BB Diogene E Baumgartel C Bennie M Bishop I. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. (2013) 4:39. 10.3389/fphar.2013.00039 23717279 [OpenAIRE] [PubMed] [DOI]

4.Kaplan W Wirtz V Mantel-Teeuwisse A Stolk P Duthey P Laing R Priority Medicines for Europe and the World. 2013 Update. Available online at: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf

5.Irazola VE Gutierrez L Bloomfield G Carrillo-Larco RM Dorairaj P Gaziano T. Hype rtension prevalence, awareness, treatment, and control in selected LMIC communities: results from the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Global Heart (2016) 11:47–59. 10.1016/j.gheart.2015.12.008 27102022 [OpenAIRE] [PubMed] [DOI]

6.International Diabetes Federation IDF Diabetes Atlas.8th ed (2017). Available online at: http://www.diabetesatlas.org

7.Cameron A Ewen M Ross-Degnan D Ball D Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet (2009) 373:240–9. 10.1016/S0140-6736(08)61762-6 19042012 [PubMed] [DOI]

8.Ofori-Asenso R Agyem an AA. Irrational use of medicines—A summary of key concepts. Pharmacy (2016) 4:35. 10.3390/pharmacy4040035 28970408 [OpenAIRE] [PubMed] [DOI]

9.Mbui JM Oluka MN Guantai EM Sinei KA Achieng L Baker A. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev Clin Pharmacol. (2017) 10:1263–71. 10.1080/17512433.2017.1371590 28831829 [OpenAIRE] [PubMed] [DOI]

10.Atieno OM Opanga S Martin A Kurdi A Godman B. Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the futur e. J Med Econ. (2018) 21:878–87. 10.1080/13696998.2018.1484372 29860920 [OpenAIRE] [PubMed] [DOI]

11.Putrik P Ramiro S Kvien TK Sokka T Pavlova M Uhlig T. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. (2014) 73:198–206. 10.1136/annrheumdis-2012-202603 23467636 [OpenAIRE] [PubMed] [DOI]

12.Kostic M Djakovic L Sujic R Godman B Jankovic SM. Inflammatory Bowel Diseases (Crohn s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Appl Health Econ Health Policy (2017) 15:85–93. 10.1007/s40258-016-0272-z 27587010 [OpenAIRE] [PubMed] [DOI]

13.Goldstein DA Clark J Tu Y Zhang J Fang F Goldstein R. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget (2017) 8:71548–55. 10.18632/oncotarget.17742 29069727 [OpenAIRE] [PubMed] [DOI]

14.Kwon H-Y Kim H Godman B. Availability and affordability of drugs with a conditional approval by the European Medicines Agency; Comparison of Korea With Other Countries and the implications. Front Pharmacol. (2018) 9:938. 10.3389/fphar.2018.00938 30233363 [OpenAIRE] [PubMed] [DOI]

15.OECD Health at a Glance 2017 - OECD Indicators. Available online at: https://read.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017_health_glance-2017-en#page1

283 references, page 1 of 19
Abstract
Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this ...
Persistent Identifiers
Subjects
Medical Subject Headings: health care economics and organizations
free text keywords: Public Health, Review, managed entry, health policy, pharmaceuticals, financing, cancer, orphan diseases, new models, managed entry ; health policy ; pharmaceuticals ; financing ; cancer ; orphan diseases ; new models, 1117 Public Health and Health Services, Science & Technology, Life Sciences & Biomedicine, Public, Environmental & Occupational Health, managed entry, health policy, pharmaceuticals, financing, cancer, orphan diseases, new models, MULTICRITERIA DECISION-ANALYSIS, HEALTH TECHNOLOGY-ASSESSMENT, MANAGED ENTRY AGREEMENTS, ENHANCE PRESCRIBING EFFICIENCY, RISK-SHARING ARRANGEMENTS, MIDDLE-INCOME COUNTRIES, PUBLIC-HEALTH, CANCER DRUGS, CASE-HISTORY, RHEUMATOID-ARTHRITIS, RM, RA0421, Health care, business.industry, business, Public economics, Scrutiny, Financial modeling, Narrative review, Health policy, Peer review, Multicriteria decision, Orphan diseases, lcsh:Public aspects of medicine, lcsh:RA1-1270
283 references, page 1 of 19

1.Garattini S Bertele V Godman B Haycox A Wettermark B Gustafsson LL. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol. (2008) 64:1137–8. 10.1007/s00228-008-0537-z 18688606 [OpenAIRE] [PubMed] [DOI]

2.Godman B Malmstrom RE Diogene E Gray A Jayathissa S Timoney A. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?Expert Rev Clin Pharmacol. (2015) 8:77–94. 10.1586/17512433.2015.990380 25487078 [OpenAIRE] [PubMed] [DOI]

3.Malmstrom RE Godman BB Diogene E Baumgartel C Bennie M Bishop I. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. (2013) 4:39. 10.3389/fphar.2013.00039 23717279 [OpenAIRE] [PubMed] [DOI]

4.Kaplan W Wirtz V Mantel-Teeuwisse A Stolk P Duthey P Laing R Priority Medicines for Europe and the World. 2013 Update. Available online at: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf

5.Irazola VE Gutierrez L Bloomfield G Carrillo-Larco RM Dorairaj P Gaziano T. Hype rtension prevalence, awareness, treatment, and control in selected LMIC communities: results from the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Global Heart (2016) 11:47–59. 10.1016/j.gheart.2015.12.008 27102022 [OpenAIRE] [PubMed] [DOI]

6.International Diabetes Federation IDF Diabetes Atlas.8th ed (2017). Available online at: http://www.diabetesatlas.org

7.Cameron A Ewen M Ross-Degnan D Ball D Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet (2009) 373:240–9. 10.1016/S0140-6736(08)61762-6 19042012 [PubMed] [DOI]

8.Ofori-Asenso R Agyem an AA. Irrational use of medicines—A summary of key concepts. Pharmacy (2016) 4:35. 10.3390/pharmacy4040035 28970408 [OpenAIRE] [PubMed] [DOI]

9.Mbui JM Oluka MN Guantai EM Sinei KA Achieng L Baker A. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev Clin Pharmacol. (2017) 10:1263–71. 10.1080/17512433.2017.1371590 28831829 [OpenAIRE] [PubMed] [DOI]

10.Atieno OM Opanga S Martin A Kurdi A Godman B. Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the futur e. J Med Econ. (2018) 21:878–87. 10.1080/13696998.2018.1484372 29860920 [OpenAIRE] [PubMed] [DOI]

11.Putrik P Ramiro S Kvien TK Sokka T Pavlova M Uhlig T. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. (2014) 73:198–206. 10.1136/annrheumdis-2012-202603 23467636 [OpenAIRE] [PubMed] [DOI]

12.Kostic M Djakovic L Sujic R Godman B Jankovic SM. Inflammatory Bowel Diseases (Crohn s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Appl Health Econ Health Policy (2017) 15:85–93. 10.1007/s40258-016-0272-z 27587010 [OpenAIRE] [PubMed] [DOI]

13.Goldstein DA Clark J Tu Y Zhang J Fang F Goldstein R. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget (2017) 8:71548–55. 10.18632/oncotarget.17742 29069727 [OpenAIRE] [PubMed] [DOI]

14.Kwon H-Y Kim H Godman B. Availability and affordability of drugs with a conditional approval by the European Medicines Agency; Comparison of Korea With Other Countries and the implications. Front Pharmacol. (2018) 9:938. 10.3389/fphar.2018.00938 30233363 [OpenAIRE] [PubMed] [DOI]

15.OECD Health at a Glance 2017 - OECD Indicators. Available online at: https://read.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017_health_glance-2017-en#page1

283 references, page 1 of 19
Any information missing or wrong?Report an Issue